261 Exclusion of subcapsular tumors prevents peritoneal seeding in hepatocellular carcinoma (HCC) patients treated with radiofrequency

Fernando Pons; Mattia Squarcia; R. Vilana; Margaret Sala; Luca Bianchi; M García Ayuso; Marı́a Varela; Josep M. Llovet; C. Brú; Jordi Bruix

doi:10.1016/s0168-8278(04)90261-9

Related publications

Article2001

Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC)

Josep M. Llovet, María Isabel Real, R. Vilana, Ramón Planas, S. Coll, John J. Aponte, Carmen Ayuso, María Sala, Jordi Muchart, R. Costa, J Rodés, Jordi Bruix

Journal of Hepatology

Article2001

Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma

Josep M. Llovet, R. Vilana, Concepció Brú, Lluís Bianchi, Jordi Bruix

Hepatology

Article2005

How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?

Myron Schwartz, Sasan Roayaie, Josep M. Llovet

Journal of Hepatology

Article2016

Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

Josep M. Llovet, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Heiko Krissel,

Article2011

645 SERUM CARBONIC ANHYDRASE 9 (CA) IS A VALUABLE BIOMARKER (BM) TO PROFILE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB AND PREDICT THEIR OUTCOME

María Reig, Loreto Boix, Alejandro Forner, Jordi Rimola, Carlos Rodríguez de Lope, J.M. López-Oliva, Silvia Tremosini, Neus Llarch, Josep M. Llovet, Carmen Ayuso, Jordi Bruix

Journal of Hepatology

261 Exclusion of subcapsular tumors prevents peritoneal seeding in hepatocellular carcinoma (HCC) patients treated with radiofrequency

Abstract

Discussion(0)

Related publications

Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC)

Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma

How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?

Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

645 SERUM CARBONIC ANHYDRASE 9 (CA) IS A VALUABLE BIOMARKER (BM) TO PROFILE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB AND PREDICT THEIR OUTCOME